Uncovering the controlling mechanisms in heparan sulfate biosynthesis
揭示硫酸乙酰肝素生物合成的控制机制
基本信息
- 批准号:8853290
- 负责人:
- 金额:$ 28.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2016-05-31
- 项目状态:已结题
- 来源:
- 关键词:AnabolismAnticoagulantsBiochemistryBiologicalBiological ProcessBlood coagulationCell ProliferationCell surfaceCellsChemicalsComplexDeacetylaseDevelopmentDisaccharidesEmbryonic DevelopmentEnsureEnzymesExhibitsExtracellular MatrixFeasibility StudiesFigs - dietaryGlucosamineGlucuronic AcidsGlycosaminoglycansGrowth FactorGrowth Factor ReceptorsHealthHeparan Sulfate BiosynthesisHeparinHeparitin SulfateHeparitin sulfotransferaseHeterogeneityIduronic AcidIn VitroInflammatory ResponseInorganic SulfatesLabelLeadLocationMass Spectrum AnalysisMediatingMethodsModelingModificationOligosaccharidesPathway interactionsPatternPhysiologicalPolymerasePolysaccharidesPositioning AttributePredispositionReactionRegulationResearchRoleSeriesSiteSpecificityStagingStreamStructureSubstrate SpecificityTestingTherapeuticUnspecified or Sulfate Ion SulfatesWorkbasedesignenzyme structureepimeraseepimerizationglycosyltransferaseindium arsenideinnovationinterestknockout genemolecular massnovelnovel strategiesreconstitutionresearch studysuccesssulfationsulfotransferase
项目摘要
DESCRIPTION (provided by applicant): Heparan sulfate (HS) is an essential glycan that is present in large quantities on the cell surface and in the extracellular matrix. HS participates ina variety of physiological and pathophysiological functions, including blood coagulation, inflammatory response and embrynic development. HS is a highly sulfated polysaccharide. Heparin, a special form of HS, is a commonly used anticoagulant drug. The uniquely distributed sulfation pattern of HS is believed to regulate its functional specificity. The wide range of biological functions of HS attracts considerable interest in understanding the mechanism for controlling the biosynthesis of HS. HS biosynthesis involves a series of specialized HS sulfotransferases, glycosyltransferases and an epimerase. Using HS biosynthetic enzymes, our labs can produce an array of HS with unique sulfation patterns and functions. Our success has proved the feasibility for studying the control of the biosynthesis of specific sulfated saccharide
sequences. Our hypothesis is that the HS biosynthesis is controlled by a series of up- stream modification steps involving N-sulfation and C5-epimerization with or without concurrent 2-O-sulfation. In this proposal, we will investigate the mechanism used by C5-epimerase and 2-O-sulfotransferase to control the synthesis of specific saccharide sequences that exhibit the anticoagulant activity and the activity in stimulating growth factors and growth factor receptor mediated cell proliferation. We will use structurally defined oligosaccharide substrates with precisely controlled N-sulfation patterns to prove the substrate specificity of C5-epimerase and 2-O-sulfotransferase. Finally, we plan to prove a unique biosynthetic pathway for preparing a highly sulfated domain that is commonly found in heparin. The success of this project will lead a comprehensive new approach to investigate the biosynthesis of HS, potentially leading to the development of novel HS-based therapeutics.
说明(申请人提供):硫酸乙酰肝素(HS)是一种重要的多糖,大量存在于细胞表面和细胞外基质中。HS参与多种生理和病理生理功能,包括凝血、炎症反应和胚胎发育。HS是一种高度硫酸盐化的多糖。肝素是HS的一种特殊形式,是一种常用的抗凝药物。HS独特的硫酸盐化模式被认为调节其功能特异性。HS的广泛生物学功能引起了人们对HS生物合成调控机制的极大兴趣。HS的生物合成涉及一系列专门的HS磺基转移酶、糖基转移酶和一种差向异构酶。使用HS生物合成酶,我们的实验室可以生产出一系列具有独特的硫酸盐化模式和功能的HS。我们的成功证明了研究特定硫酸盐糖生物合成控制的可行性。
序列。我们的假设是,HS的生物合成是由一系列上游修饰步骤控制的,包括N-硫化和C5-异构化,以及是否同时进行2-O-硫化。在这个方案中,我们将研究C5-差向异构酶和2-O-磺基转移酶控制特定糖序列的合成的机制,这些糖序列具有抗凝血活性和刺激生长因子和生长因子受体介导的细胞增殖的活性。我们将使用具有精确控制的N-硫化模式的结构定义的寡糖底物来证明C5-差向异构酶和2-O-磺基转移酶的底物专一性。最后,我们计划证明一种独特的生物合成途径,用于制备肝素中常见的高度硫酸盐化结构域。该项目的成功将引领一种全面的新方法来研究HS的生物合成,可能导致基于HS的新型疗法的开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JIAN LIU其他文献
JIAN LIU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JIAN LIU', 18)}}的其他基金
The role of heparan sulfate in cathepsin K biology
硫酸乙酰肝素在组织蛋白酶 K 生物学中的作用
- 批准号:
10665752 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Development of a New Carbohydrate-based Anticoagulant Drug
新型碳水化合物抗凝药物的开发
- 批准号:
9408360 - 财政年份:2017
- 资助金额:
$ 28.47万 - 项目类别:
PROBING HEPARIN STRUCTURAL ELEMENTS FOR HIGH RISK OF HEPARIN-INDUCED THROMBOCYTOP
探测肝素诱导血小板高风险的肝素结构元件
- 批准号:
8730574 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
Uncovering the controlling mechanisms in heparan sulfate biosynthesis
揭示硫酸乙酰肝素生物合成的控制机制
- 批准号:
8576941 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
PROBING HEPARIN STRUCTURAL ELEMENTS FOR HIGH RISK OF HEPARIN-INDUCED THROMBOCYTOP
探测肝素诱导血小板高风险的肝素结构元件
- 批准号:
9135956 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
PROBING HEPARIN STRUCTURAL ELEMENTS FOR HIGH RISK OF HEPARIN-INDUCED THROMBOCYTOP
探测肝素诱导血小板高风险的肝素结构元件
- 批准号:
9336703 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
PROBING HEPARIN STRUCTURAL ELEMENTS FOR HIGH RISK OF HEPARIN-INDUCED THROMBOCYTOP
探测肝素诱导血小板高风险的肝素结构元件
- 批准号:
8703471 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
Uncovering the controlling mechanisms in heparan sulfate biosynthesis
揭示硫酸乙酰肝素生物合成的控制机制
- 批准号:
8724523 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
PROBING HEPARIN STRUCTURAL ELEMENTS FOR HIGH RISK OF HEPARIN-INDUCED THROMBOCYTOP
探测肝素诱导血小板高风险的肝素结构元件
- 批准号:
8892053 - 财政年份:2013
- 资助金额:
$ 28.47万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 28.47万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 28.47万 - 项目类别:
Studentship Programs